Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q2 2025 value amounting to $1000.0.

  • Whitehawk Therapeutics' Capital Expenditures fell 9981.52% to $1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $738000.0, marking a year-over-year decrease of 6768.83%. This contributed to the annual value of $1.7 million for FY2024, which is 5835.85% down from last year.
  • As of Q2 2025, Whitehawk Therapeutics' Capital Expenditures stood at $1000.0, which was down 9981.52% from $551000.0 recorded in Q1 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Capital Expenditures peaked at $1.4 million during Q1 2023, and registered a low of $1000.0 during Q2 2025.
  • For the 5-year period, Whitehawk Therapeutics' Capital Expenditures averaged around $444533.3, with its median value being $237000.0 (2022).
  • Per our database at Business Quant, Whitehawk Therapeutics' Capital Expenditures skyrocketed by 497037.04% in 2023 and then plummeted by 9981.52% in 2025.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Capital Expenditures stood at $46000.0 in 2021, then surged by 69.57% to $78000.0 in 2022, then surged by 946.15% to $816000.0 in 2023, then plummeted by 77.21% to $186000.0 in 2024, then crashed by 99.46% to $1000.0 in 2025.
  • Its Capital Expenditures was $1000.0 in Q2 2025, compared to $551000.0 in Q1 2025 and $186000.0 in Q4 2024.